首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Chinese Journal Of Cancer Research

Chinese Journal Of Cancer Research杂志,由Springer Berlin Heidelberg出版,于1988年创刊,Quarterly,出版语言English,ISSN:1000-9604,E-ISSN:1993-0631。

投稿咨询
Chinese Journal Of Cancer Research
Chinese Journal Of Cancer Research
Chinese Journal Of Cancer Research
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
6.7
CiteScore
7.9
期刊收录
SCI、SCIE

Chinese Journal Of Cancer Research(中文译名:《中国癌症研究杂志》),ISSN:1000-9604,EISSN:1993-0631,是Springer Berlin Heidelberg出版的国际性学术期刊,创刊于1988年,以Quarterly形式稳定发行,2026年总发文量约66篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达6.7,2025年期刊CiteScore为7.9,2025年期刊自引率约14.9%,在中科院期刊分区体系中位列医学大类1区,在所属学科领域具备高学术影响力与国际认可度。Chinese Journal Of Cancer Research长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约4.5月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,CHINA MAINLANDUSA、South Korea、Brazil、Japan、France、Italy等为核心发文国家与地区;PEKING UNIVERSITYCHINESE ACADEMY OF MEDICAL SCIENCES - PEKING UNION MEDICAL COLLEGE、PEKING UNIV CANC HOSP & INST、SUN YAT SEN UNIVERSITY、TIANJIN MEDICAL UNIVERSITY、FUDAN UNIVERSITY、SHANGHAI JIAO TONG UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
2区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
3区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
3区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 58 / 333

82.7

学科:ONCOLOGY SCIE Q1 76 / 333

77.33

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 51 / 328

84.6

学科:ONCOLOGY SCIE Q2 90 / 328

72.71


中国学者近期发文

1
Expert consensus on multidisciplinary management of laparoscopic-endoscopic cooperative surgery combined with sentinel lymph node navigation surgery for early gastric cancer (2026 edition

Author:Zheng, Zhi; Zhao, Yu; Xu, Rui; Wang, Zimeng; Yin, Jie; Meng, Fandong; Liu, Kuiliang; Chen, Guangyong; Zhang, Jun; Li, Peng; Chen, Lin; Zhang, Zhongtao; Zhang, Shutian

Journal: CHINESE JOURNAL OF CANCER RESEARCH. 2026; Vol. 38, Issue 1, pp. -. DOI: 10.21147/j.issn.1000-9604.2026.01.01

2
Evaluating diagnostic efficacy of multigene testing in non-diagnostic thyroid nodules by fine-needle aspiration cytology: A prospective cohort stud

Author:Zhang, Guozhi; Ren, Lin; Xiao, Jia; Bao, Yangqiu; Tian, Hao; Shi, Qiyun; Tang, Chunlin; Chen, Ping; Liang, Yan; Tang, Peng; Yan, Wenting; Zhang, Ye; Qi, Xiaowei; Guo, Yanli; Zhang, Yi

Journal: CHINESE JOURNAL OF CANCER RESEARCH. 2026; Vol. 38, Issue 1, pp. -. DOI: 10.21147/j.issn.1000-9604.2026.01.02

3
Circulating tumor cells with chromosome 8 aneuploidy are a diagnostic and prognostic monitoring biomarker for ovarian cance

Author:Yang, Shimin; Li, Buyun; Cheng, Hongyan; Ye, Xue; Dou, Sha; Wang, Yuanfen; Song, Xuelian; Yang, Huarui; Chang, Xiaohong; Li, Yi

Journal: CHINESE JOURNAL OF CANCER RESEARCH. 2026; Vol. 38, Issue 1, pp. -. DOI: 10.21147/j.issn.1000-9604.2026.01.05

4
Chromatin regulators TOP2A and PPARGC1A stratify prostate cancer risk and reveal TOP2A-driven progression via PI3K/AKT pathwa

Author:Wang, Zhipeng; Wang, Jie; Chen, Shuang; Wu, Ruicheng; Tuo, Zhouting; Ye, Luxia; Yoo, Koo Han; Li, Dengxiong; Jin, Xiaodong; Xiong, Wei; Feng, Dechao

Journal: CHINESE JOURNAL OF CANCER RESEARCH. 2026; Vol. 38, Issue 1, pp. -. DOI: 10.21147/j.issn.1000-9604.2026.01.06

5
Chemotherapy-free regimen: Real-world efficacy and safety of anlotinib plus PD-1/PD-L1 inhibitors in advanced non-small cell lung cance

Author:Chen, Haiyang; Yang, Guanghua; Wang, Tao; Chen, Gongbin; Xu, Aiguo; Ma, Chunzheng; Shang, Ke; Liu, Peijie; Zhou, Honglin; Wang, Zhiwei; Xu, Xinju; Sun, Xiao; Zhai, Fengyu; Ji, Yuanyuan; Huangfu, Juan; Jia, Xinli; Li, Chunqing; Mei, Jiazhuan; Jia, Minyong; Niu, Shunhai; Zhang, Gaogao; Liu, Yuqing; Lu, Lin; Zhang, Juntao; Wang, Lijun; Ma, Tianjiang; Gao, Liwei; Jin, Cailing; Wang, Qiming

Journal: CHINESE JOURNAL OF CANCER RESEARCH. 2026; Vol. 38, Issue 1, pp. -. DOI: 10.21147/j.issn.1000-9604.2026.01.03

6
Frontiers in bacterial outer membrane vesicles: From basic characteristics to cancer therap

Author:Ma, Siyang; Sun, Jianxuan; Xu, Jingyu; An, Ye; Xu, Jinzhou; Wang, Shaogang; Xia, Qidong

Journal: CHINESE JOURNAL OF CANCER RESEARCH. 2026; Vol. 38, Issue 1, pp. -. DOI: 10.21147/j.issn.1000-9604.2026.01.07

7
Optimal response population after neoadjuvant therapy for patients with locally advanced gastric cancer: A multicenter stud

Author:Zhong, Qing; Sun, Yuqin; Lian, Mingqiao; Wang, Zengbin; Li, Baolong; Yu, Junhua; Ma, Yubin; Wu, Shichao; Wang, Yonghong; Wu, Ju; Zhu, Jiyun; Ye, Wen; Zhang, Zhiquan; Weng, Caiming; Wu, Dong; Chen, Qiuxian; Chen, Qiyue; Li, Ping; Zheng, Chaohui; Cai, Lisheng; Huang, Changming

Journal: CHINESE JOURNAL OF CANCER RESEARCH. 2025; Vol. 37, Issue 2, pp. -. DOI: 10.21147/j.issn.1000-9604.2025.02.05

8
Context-dependent roles of 5-HT and its receptors in tumor growth and wound healing: Mechanisms and therapeutic implication

Author:Zeng, Qingya; Zhu, Jiaojiao; He, Zongyun; Qin, Hong; Zhou, Wenhu; Hua, Fangqi; Yang, Jin

Journal: CHINESE JOURNAL OF CANCER RESEARCH. 2025; Vol. 37, Issue 2, pp. -. DOI: 10.21147/j.issn.1000-9604.2025.02.11

9
Genomic spectra of lymphovascular invasion in breast cance

Author:Shen, Chuhan; Lin, Caijin; Qu, Feilin; Chen, Chao; Shao, Zhiming; Jiang, Yizhou; Hu, Xin; Di, Genhong

Journal: CHINESE JOURNAL OF CANCER RESEARCH. 2025; Vol. 37, Issue 2, pp. -. DOI: 10.21147/j.issn.1000-9604.2025.02.02

10
Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma: A single-center,-arm clinical trial (vol 37, 296, 2025

Author:Ren, Yupeng; Li, Yuxuan; Cao, Mingbo; Yao, Zhicheng; Tang, Yongchang; Yuan, Feng; Yang, Gaoyuan; He, Zhiwei; Shi, Zheng; Su, Xiaorui; Deng, Meihai

Journal: CHINESE JOURNAL OF CANCER RESEARCH. 2025; Vol. 37, Issue 2, pp. -. DOI: 10.21147/j.issn.1000-9604.2025.02.14


在线咨询

Chinese Journal Of Cancer Research

国际简称:CHINESE J CANCER RES参考译名:中国癌症研究杂志

年发文量:66 CiteScore:7.9 是否预警:否 Gold OA文章占比:100.00% 研究类文章占比:80.30%

杂志社联系方式:SPRINGER, 233 SPRING ST, NEW YORK, USA, NY, 10013

Chinese Journal Of Cancer Research